With respect to the wider GLP-1 drug class, the UK SmPCs for semaglutide (available on the electronic Medicines Compendium, emc) and tirzepatide (Mounjaro SmPC, emc) document GI adverse effects including nausea, vomiting, diarrhoea, constipation, and dyspepsia as well-characterised class effects
Her results speak for themselves
Current Diabetes Reviews , 17 (3), 293303
However, individuals with a BMI as low as 27 may be eligible for Semaglutide if they have specific conditions such as hypertension, type 2 diabetes, or high cholesterol
Certain conditions, like a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, can make these medications unsuitable
ipamorelin